Ianalumab for the Treatment of Patients with Sjögren’s Disease
New England Journal of Medicine · 22.10.2026 · 395 (16) · 1585-1599
DOI: 10.1056/nejmoa2601088 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 22.10.2026. Verfasst von Xavier Mariette und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM, Commissariat à l'Énergie Atomiqu…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sjogren's Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Novartis Pharma AG, Basel, Switzerland.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM, Commissariat à l'Énergie Atomique, Unité Mixte de Recherche (UMR) 1184 (Immunological Diseases, Microb…
- Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore.
- Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
- Division of Rheumatology, Medical College of Georgia at Augusta University, Augusta.
- Division of Oral Medicine, Tufts School of Dental Medicine, Boston.
- Department of Rheumatology, Brest University Centre Hospitalier Universitaire de Brest, INSERM UMR 1227, Lymphocytes B et Autoimmunité, Brest, France.
ORCID-Profile: Xavier Mariette, Hiroki Ozawa, Thomas Dörner, Sara S McCoy
Förderung
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Mariette, X., Grader-Beck, T., Finzel, S., Schiopu, E., Papas, A., Devauchelle-Pensec, V., Sopala, M., Zeng, X., Noaiseh, G., Takeuchi, T., Kumar, U., Hermann, J., Ozawa, H., Fox, R., Zong, S., Narayanswamy, D., Li, X., Luo, W. L., Woznicki, J., …, & NEPTUNUS-2 Investigators (2026). Ianalumab for the Treatment of Patients with Sjögren’s Disease. New England Journal of Medicine, 395(16), 1585-1599. https://doi.org/10.1056/nejmoa2601088
Vancouver
Mariette X, Grader-Beck T, Finzel S, Schiopu E, Papas A, Devauchelle-Pensec V, et al. Ianalumab for the Treatment of Patients with Sjögren’s Disease. New England Journal of Medicine. 2026;395(16):1585-1599. doi:10.1056/nejmoa2601088
BibTeX
@article{Mariette2026,
author = {Mariette, Xavier and Grader-Beck, Thomas and Finzel, Stephanie and Schiopu, Elena and Papas, Athena and Devauchelle-Pensec, Valerie and Sopala, Monika and Zeng, Xiaofeng and Noaiseh, Ghaith and Takeuchi, Tsutomu and Kumar, Uma and Hermann, Josef and Ozawa, Hiroki and Fox, Robert and Zong, Susan and Narayanswamy, Deepak and Li, Xiaomei and Luo, Wen-Lin and Woznicki, Janice and Debonnett, Laurie and Zhu, Xuan and He, Linchen and Matzkies, Franziska and Jahreis, Angelika and Jain, Devendra Kumar and Porter, Brian and Lau, Carol and Dörner, Thomas and McCoy, Sara S and Bowman, Simon J and Hueber, Wolfgang and NEPTUNUS-1 and NEPTUNUS-2 Investigators, NEPTUNUS-1 and NEPTUNUS-2 Investigators and NEPTUNUS-1 Investigators, NEPTUNUS-1 Investigators and NEPTUNUS-2 Investigators, NEPTUNUS-2 Investigators},
title = {Ianalumab for the Treatment of Patients with Sjögren’s Disease},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {16},
pages = {1585--1599},
doi = {10.1056/nejmoa2601088}
}
EUVIMED